Healthcare Industry News: dilatation catheter
News Release - August 23, 2010
Svelte Medical Systems, Inc. Receives CE Mark Approval to Market the Svelte Acrobat Stent-on-a-Wire (SOAW) Coronary Stent SystemNEW PROVIDENCE, N.J.--(Healthcare Sales & Marketing Network)--Svelte™ Medical Systems, Inc. is pleased to announce that it has officially received the CE Mark to market its Acrobat Stent-on-a-Wire (SOAW) Bare Metal Coronary Stent System in the European Union. The Acrobat SOAW stenting system has been shown in clinical trials to facilitate direct stenting and has the potential to provide substantial procedural time and cost savings. These savings are realized by eliminating the need for a coronary guidewire and balloon dilatation catheters. Furthermore, the Acrobat stent allows reduced use of contrast medium which is a benefit to many patients. Another important advantage when using the Acrobat stenting system is that the operator and patient radiation dosing is significantly reduced. The extremely low crossing profile of the Acrobat stent makes it well suited for stenting via the radial artery approach which provides additional comfort and safety benefits to the patient.
The Company plans to initiate U.S. clinical trials on the Acrobat SOAW technology in 2011. A drug eluting version of the Acrobat stent is now under development using a novel non-inflammatory carrier for the drug.
To enhance the familiarity with the Acrobat stent product for physicians, Svelte Medical Systems will be exhibiting at the European Society of Cardiology (ESC) Congress in Stockholm, Sweden August 28 – September 1st. Additional details about Svelte’s products are available at www.sveltemedical.com.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
Source: Svelte Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.